A number of other equities analysts have also commented on AZN. Shore Capital reiterated a buy rating on shares of AstraZeneca in a report on Thursday, November 9th. Barclays restated an overweight rating and issued a £135 ($168.90) target price on shares of AstraZeneca in a report on Tuesday, September 12th. Deutsche Bank Aktiengesellschaft restated a hold rating on shares of AstraZeneca in a report on Tuesday, October 3rd. Citigroup restated a buy rating on shares of AstraZeneca in a report on Monday, October 2nd. Finally, Morgan Stanley boosted their target price on shares of AstraZeneca from £127 ($158.89) to £129 ($161.39) in a report on Monday, September 25th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of £118.05 ($147.69).
AstraZeneca Stock Performance
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Five stocks we like better than AstraZeneca
- Transportation Stocks Investing
- The most upgraded stocks in November have two things in common
- Earnings Per Share Calculator: How to Calculate EPS
- Monday.com rocked earnings like it’s the weekend
- What Are Dividend Achievers? An Introduction
- Plan to own one retailer? Make it this one
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.